Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labo EuromedisFRA:61R +5.65%60 Cash Ratio is 1.47 as of Dec. 2025, which is 4% above its 10-year median of 1.42. GuruFocus rates FRA:61R with a GF Score™ of 60/100 and a GF Value™ of €4.42. The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, Labo Euromedis ranks better than 93.28% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Labo Euromedis Cash Ratio Related Terms
Labo Euromedis Cash Ratio Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Labo Euromedis's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Cash Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (FRA:61R) has a Cash Ratio of 1.47 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Labo Euromedis and its competitors. This is near median its historical median of 1.42. Over the past decade, Labo Euromedis' Cash Ratio has ranged from 0.04 to 2.81. According to the industry distribution chart, Labo Euromedis ranks #8 out of 119 companies in the Medical Distribution industry, placing it in the top 6.7%.
Is Labo Euromedis' Cash Ratio too high?
Labo Euromedis' current Cash Ratio of 1.47 is near median its 10-year median of 1.42. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 2.81. The Medical Distribution industry median Cash Ratio is 0.18. Labo Euromedis' value of 1.47 is 716.7% above this industry median. Based on the distribution chart, Labo Euromedis ranks #8 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Labo Euromedis has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Cash Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #8 out of 119 companies for Cash Ratio. This places Labo Euromedis in the top 7% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.18. Labo Euromedis' value of 1.47 is 716.7% above this benchmark. Historically, Labo Euromedis' own Cash Ratio has ranged from 0.04 to 2.81 over the past decade. While the company's 10-year median is 1.42 vs. the industry median of 0.18, Labo Euromedis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Distribution company?
The median Cash Ratio among Medical Distribution companies is 0.18, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current Cash Ratio of 1.47 is 716.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median Cash Ratio is 0.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Cash Ratio is 1.47, which is near median its own 10-year median of 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current Cash Ratio of 1.47. The stock's GF Value™ is €4.42, compared to a current price of €5.05 — trading 14.3% above its estimated fair value. The current Cash Ratio is 1.47, which is near median its 10-year median of 1.42 and 716.7% above the Medical Distribution industry median of 0.18. Labo Euromedis' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current Cash Ratio is 1.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €5.05 is trading 14.3% above its estimated GF Value™ of €4.42.
Key valuation signals for FRA:61R:
Cash Ratio: 1.47 (near median its 10-year median of 1.42)
GF Value™: €4.42 vs. price of €5.05 (14.3% above fair value)
Industry Position: 716.7% above the Medical Distribution median (#8 of 119)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
60GF Score
Get the complete analysis for FRA:61R
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
